🚀 VC round data is live in beta, check it out!
Genomictree Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genomictree and similar public comparables like OmniAb, Korro Bio, Diaceutics, Nautilus Biotechnology and more.
Genomictree Overview
About Genomictree
Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market.
Founded
2000
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$226M
Genomictree Financials
Genomictree reported last fiscal year revenue of $3M and negative EBITDA of ($5M).
In the same fiscal year, Genomictree generated $482K in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
Genomictree P&L
In the most recent fiscal year, Genomictree reported revenue of $3M and EBITDA of ($5M).
Genomictree expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $482K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (205%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (300%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (239%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genomictree Stock Performance
Genomictree has current market cap of $277M, and enterprise value of $226M.
Market Cap Evolution
Genomictree's stock price is $11.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $226M | $277M | 0.8% | XXX | XXX | XXX | $-0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenomictree Valuation Multiples
Genomictree trades at 89.2x EV/Revenue multiple, and (43.5x) EV/EBITDA.
Genomictree Financial Valuation Multiples
As of April 14, 2026, Genomictree has market cap of $277M and EV of $226M.
Equity research analysts estimate Genomictree's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genomictree has a P/E ratio of (45.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV (current) | $226M | XXX | $226M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 89.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (43.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (29.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 469.5x | XXX | XXX | XXX |
| P/E | — | XXX | (45.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (25.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genomictree Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genomictree Margins & Growth Rates
Genomictree's revenue in the last fiscal year grew by 59%.
Genomictree Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 59% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (205%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (13%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 101% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genomictree Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Korro Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Diaceutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nautilus Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Quantum-Si | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomictree M&A Activity
Genomictree acquired XXX companies to date.
Last acquisition by Genomictree was on XXXXXXXX, XXXXX. Genomictree acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genomictree
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenomictree Investment Activity
Genomictree invested in XXX companies to date.
Genomictree made its latest investment on XXXXXXXX, XXXXX. Genomictree invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genomictree
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genomictree
| When was Genomictree founded? | Genomictree was founded in 2000. |
| Where is Genomictree headquartered? | Genomictree is headquartered in South Korea. |
| Is Genomictree publicly listed? | Yes, Genomictree is a public company listed on Korea Exchange. |
| What is the stock symbol of Genomictree? | Genomictree trades under 228760 ticker. |
| When did Genomictree go public? | Genomictree went public in 2016. |
| Who are competitors of Genomictree? | Genomictree main competitors are OmniAb, Korro Bio, Diaceutics, Nautilus Biotechnology. |
| What is the current market cap of Genomictree? | Genomictree's current market cap is $277M. |
| What is the current revenue of Genomictree? | Genomictree's last fiscal year revenue is $3M. |
| What is the current EV/Revenue multiple of Genomictree? | Current revenue multiple of Genomictree is 89.2x. |
| Is Genomictree profitable? | No, Genomictree is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.